ALGEN Fundamental Analysis - GENOWAY SA

Fundamental Rating

ALGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGEN was profitable.

In the past year ALGEN had a positive cash flow from operations.

In multiple years ALGEN reported negative net income over the last 5 years.

In multiple years ALGEN reported negative operating cash flow during the last 5 years.

1.2 Ratios

ALGEN has a Return On Assets of 3.96%. This is in the better half of the industry: ALGEN outperforms 76.54% of its industry peers.

ALGEN has a Return On Equity of 7.06%. This is in the better half of the industry: ALGEN outperforms 76.54% of its industry peers.

ALGEN has a better Return On Invested Capital (6.13%) than 80.25% of its industry peers.

The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 11.80%.

The 3 year average ROIC (5.56%) for ALGEN is below the current ROIC(6.13%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROIC	6.13%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

1.3 Margins

ALGEN has a better Profit Margin (5.86%) than 79.01% of its industry peers.

With a decent Operating Margin value of 8.09%, ALGEN is doing good in the industry, outperforming 75.31% of the companies in the same industry.

Looking at the Gross Margin, with a value of 92.34%, ALGEN belongs to the top of the industry, outperforming 87.65% of the companies in the same industry.

ALGEN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	8.09%
PM (TTM)	5.86%
GM	92.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.

ALGEN has less shares outstanding than it did 1 year ago.

ALGEN has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ALGEN has been reduced compared to a year ago.

2.2 Solvency

ALGEN has an Altman-Z score of 2.34. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.

The Altman-Z score of ALGEN (2.34) is better than 67.90% of its industry peers.

The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.

ALGEN has a better Debt to FCF ratio (1.41) than 85.19% of its industry peers.

ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.

ALGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Altman-Z	2.34

ROIC/WACC0.87

WACC7.05%

2.3 Liquidity

ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.

ALGEN's Current ratio of 1.92 is in line compared to the rest of the industry. ALGEN outperforms 43.21% of its industry peers.

ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.81, ALGEN perfoms like the industry average, outperforming 45.68% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.92
Quick Ratio	1.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.41% over the past year.

The Revenue has grown by 10.04% in the past year. This is quite good.

ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.

ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.90, ALGEN is valued correctly.

Based on the Price/Earnings ratio, ALGEN is valued cheaper than 90.12% of the companies in the same industry.

ALGEN is valuated cheaply when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	12.9
Fwd PE	N/A

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 91.36% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, ALGEN is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	5.67
EV/EBITDA	4.49

4.3 Compensation for Growth

ALGEN has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.42%

EPS Next 3Y0%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALGEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENOWAY SA

EPA:ALGEN (12/31/2025, 7:00:00 PM)

2.71

-0.06 (-2.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners5.68%

Inst Owner ChangeN/A

Ins Owners10.39%

Ins Owner ChangeN/A

Market Cap25.69M

Revenue(TTM)22.06M

Net Income(TTM)1.26M

Analysts86.67

Price Target6.02 (122.14%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	12.9
Fwd PE	N/A
P/S	1.2
P/FCF	5.67
P/OCF	3.72
P/B	1.44
P/tB	2.11
EV/EBITDA	4.49

EPS(TTM)0.21

EY7.75%

EPS(NY)0

Fwd EYN/A

FCF(TTM)0.48

FCFY17.64%

OCF(TTM)0.73

OCFY26.89%

SpS2.26

BVpS1.88

TBVpS1.28

PEG (NY)N/A

PEG (5Y)N/A

Graham Number2.98

Profitability

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROCE	7.62%
ROIC	6.13%
ROICexc	7.79%
ROICexgc	11.35%
OM	8.09%
PM (TTM)	5.86%
GM	92.34%
FCFM	21.15%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

ROICexc(3y)6.94%

ROICexc(5y)N/A

ROICexgc(3y)9.99%

ROICexgc(5y)N/A

ROCE(3y)6.91%

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

F-Score5

Asset Turnover0.68

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Debt/EBITDA	0.77
Cap/Depr	55.06%
Cap/Sales	11.1%
Interest Coverage	250
Cash Conversion	114.18%
Profit Quality	360.76%
Current Ratio	1.92
Quick Ratio	1.81
Altman-Z	2.34

F-Score5

WACC7.05%

ROIC/WACC0.87

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

EBIT growth 1Y0.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year200%

EBIT Next 3Y68.69%

EBIT Next 5YN/A

FCF growth 1Y308.02%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y1010.09%

OCF growth 3YN/A

OCF growth 5YN/A

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.

What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.

What is the profitability of ALGEN stock?

GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.

Can you provide the PE and PB ratios for ALGEN stock?

The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 12.9 and the Price/Book (PB) ratio is 1.44.

What is the financial health of GENOWAY SA (ALGEN.PA) stock?

The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

What is the profitability of ALGEN stock?

Can you provide the PE and PB ratios for ALGEN stock?

What is the financial health of GENOWAY SA (ALGEN.PA) stock?